Therapeutic efficacy was evaluated under both monotherapy and combination regimens with gemcitabine/bisphosphonate or anti-PD-1.<h4>Results</h4>SRC phosphorylation regulated the activation of cytoskeletal regulators FAK and paxillin, thereby controlling cancer cell motility. This evidence concerns the gene PTK2 and cancer.